The atypical anti-psychotic clozapine decreases bone mass in rats in vivo

Schizophrenia Research

Volumn 126, Issue 1-3, 2011, Pages 291-297

  Costa, Jessica L ^a   Smith, Greg ^a   Watson, Maureen ^a   Lin, Jian Ming ^a   Callon, Karen ^a   Gamble, Greg ^a   Cheng, Anthony ^a   Vickers, Mark H ^a   Shepherd, Peter R ^a   Cornish, Jillian ^a   Grey, Andrew ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Anti psychotic; Bone density; Osteoblast; Osteoporosis

Indexed keywords

CLOZAPINE; CORTICOSTERONE; HALOPERIDOL; TESTOSTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CORTICAL BONE; CORTICOSTERONE BLOOD LEVEL; DOPAMINERGIC ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRO-COMPUTED TOMOGRAPHY; MITOGENESIS; NONHUMAN; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; RAT; SIGNAL DETECTION; TESTOSTERONE BLOOD LEVEL; TRABECULAR BONE;

ABSORPTIOMETRY, PHOTON; ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CLOZAPINE; HALOPERIDOL; MALE; OSTEOBLASTS; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE; THYMIDINE; TIME FACTORS; TRITIUM;

EID: 79952006593     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.11.024     Document Type: Article

References (29)

1. Alaniz R.C., Thomas S.A., Perez-Melgosa M., Mueller K., Farr A.G., Palmiter R.D., Wilson C.B. Dopamine beta-hydroxylase deficiency impairs cellular immunity. Proc. Natl Acad. Sci. USA 1999, 96:2274-2278.
2. Bilici M., Cakirbay H., Guler M., Tosun M., Ulgen M., Tan U. Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int. J. Neurosci. 2002, 112:817-828.
3. Bliziotes M. Update in serotonin and bone. J. Clin. Endocrinol. Metab. 2010, 95:4124-4132.
4. Bliziotes M., McLoughlin S., Gunness M., Fumagalli F., Jones S.R., Caron M.G. Bone histomorphometric and biomechanical abnormalities in mice homozygous for deletion of the dopamine transporter gene. Bone 2000, 26:15-19.
5. Citrome L., Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv. Rev. Psychiatry 2002, 10:280-291.
6. Collet C., Schiltz C., Geoffroy V., Maroteaux L., Launay J.M., de Vernejoul M.C. The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J. 2008, 22:418-427.
7. Cornish J., Callon K.E., Lin C.Q., Xiao C.L., Mulvey T.B., Cooper G.J., Reid I.R. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am. J. Physiol. 1999, 277:E779-E783.
8. Cornish J., Callon K.E., Bava U., Lin C., Naot D., Hill B.L., Grey A.B., Broom N., Myers D.E., Nicholson G.C., et al. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J. Endocrinol. 2002, 175:405-415.
9. Cornish J., MacGibbon A., Lin J.-M., Watson M., Callon K.E., Tong P.C., Dunford J.E., van der Does Y., Williams G.A., Grey A.B., et al. Modulation of osteoclastogenesis by fatty acids. Endocrinology 2008, 149:5688-5695.
10. Freedman R. Schizophrenia. N. Engl. J. Med. 2003, 349:1738-1749.
11. Grey A., Banovic T., Naot D., Hill B., Callon K., Reid I., Cornish J. Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not p42/44 mitogen-activated protein kinases. Endocrinology 2001, 142:1098-1106.
12. Gustafsson B.I., Thommesen L., Stunes A.K., Tommeras K., Westbroek I., Waldum H.L., Slordahl K., Tamburstuen M.V., Reseland J.E., Syversen U. Serotonin and fluoxetine modulate bone cell function in vitro. J. Cell. Biochem. 2006, 98:139-151.
13. Gustafsson B.I., Westbroek I., Waarsing J.H., Waldum H., Solligard E., Brunsvik A., Dimmen S., van Leeuwen J.P., Weinans H., Syversen U. Long-term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats. J. Cell. Biochem. 2006, 97:1283-1291.
14. Halbreich U., Rojanksy N., Palter S., Hreshchyshyn M., Kreeger J., Bakhai Y., Rosan R. Decreased bone mineral density in medicated psychiatric patients. Psychosom. Med. 1995, 57:485-491.
15. Hall T.J., Nyugen H., Schaeublin M., Michalsky M., Missbach M. Phenothiazines are potent inhibitors of osteoclastic bone resorption. Gen. Pharmacol. 1996, 27:845-848.
16. Howard L., Kirkwood G., Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br. J. Psychiatry 2006, 190:129-134.
17. Hugenholtz G.W.K., Heerdink E.R., van Staa T.P., Nolena W.A., Egberts A.C.G. Risk of hip/femur fractures in patients using antipsychotics. Bone 2005, 37:864-870.
18. Markianos M., Hatzimanolis J., Lykouras L. Switch from neuroleptics to clozapine does not influence pituitary-gonadal axis hormone levels in male schizophrenic patients. Eur. Neuropsychopharmacol. 1999, 9:533-536.
19. McGrath J., Saha S., Welham J., El Saadi O., MacCauley C., Chant D. A systematic review of the incidence of schizophrenia: the distribution of rates and the influence of sex, urbanicity, migrant status and methodology. BMC Med. 2004, 2:13.
20. O'Sullivan S., Naot D., Callon K., Porteous F., Horne A., Wattie D., Watson M., Cornish J., Browett P., Grey A. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J. Bone Miner. Res. 2007, 22:1679-1689.
21. Pouwels S., van Staa T.P., Egberts A.C.G., Leufkens H.G.M., Cooper C., de Vries F. Antipsychotic use and the risk of hip/femur fracture: a population-based case-control study. Osteoporos. Int. 2009, 20:1499-1506.
22. Reid I.R. Relationships between fat and bone. Osteoporos. Int. 2008, 19:595-606.
23. Smith G.C., Chaussade C., Vickers M., Jensen J., Shepherd P.R. Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologica 2008, 51:2309-2317.
24. Smith G.C., Vickers M.H., Cognard E., Shepherd P.R. Clozapine and quetiapine acutely reduce glucagon-like peptide-1 production and increase glucagon release in obese rats: implications for glucose metabolism and food choice behaviour. Schizophr. Res. 2009, 115:30-40.
25. Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., Armstrong D., Ducy P., Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002, 111:305-317.
26. Warden S.J., Robling A.G., Sanders M.S., Bliziotes M.M., Turner C.H. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005, 146:685-693.
27. Williams G.A., Wang Y., Callon K.E., Watson M., Lin J.-m., Lam J.B.B., Costa J.L., Orpe A., Broom N., Naot D., et al. In vitro and in vivo effects of adiponectin on bone. Endocrinology 2009, 150:3603-3610.
28. Yadav V.K., Ryu J.H., Suda N., Tanaka K.F., Gingrich J.A., Schutz G., Glorieux F.H., Chiang C.Y., Zajac J.D., Insogna K.L., et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825-837.
29. Yadav V.K., Oury F., Suda N., Liu Z.W., Gao X.B., Confavreux C., Klemenhagen K.C., Tanaka K.F., Gingrich J.A., Guo X.E., et al. A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 2009, 138:976-989.